Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts
Baxter
Dow
Medtronic

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Litigation Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2014)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-10-10
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties NOVARTIS AG; NOVARTIS PHARMACEUTICALS CORPORATION; PAR PHARMACEUTICAL INC.
Patents 5,665,772; 6,004,973; 6,239,124; 6,455,518
Attorneys Daniel M. Silver; Michael P. Kelly; Steven J. Fineman
Link to Docket External link to docket
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-10-10 1 United States Letters Patent No. 5,665,772 (“the ‘772 patent”). The ‘772 patent was duly and legally …United States Letters Patent No. 6,004,973 (“the ‘973 patent”). The ‘973 patent was duly and legally …United States Letters Patent No. 6,455,518 (“the ‘518 patent”). The ‘518 patent was duly and legally …the ‘772, ‘973, and ‘518 patents was an act of infringement of those patents. 23. … COMPLAINT FOR PATENT INFRINGEMENT filed against Par Pharmaceutical Inc. - Magistrate Consent Notice External link to document
2016-04-04 104 Roush, Ph.D. Regarding the Validity of U.S. Patent No. 5,665,772, (2) Sur-Reply Expert Report of Dr. Howard…III Regarding the Nonobviousness of U.S. Patent No. 5,665,772, (3) Sur-Reply Expert Report of Uwe Christians…Navia, Ph.D. Regarding the Validity of U.S. Patent No. 5,665,772, and (5) Sur-Reply Expert Report of John…FACS, FAASLD Regarding the Validity of U.S. Patent No. 5,665,772 filed by Novartis AG, Novartis Pharmaceuticals… 10 October 2014 1:14-cv-01289 830 Patent None District Court, D. Delaware External link to document
2016-09-26 148 the Invalidity of U.S. Patent No. 5,665,772 for Obviousness-Type Double Patenting, by Par Pharmaceutical… 10 October 2014 1:14-cv-01289 830 Patent None District Court, D. Delaware External link to document
2016-09-26 149 Invalidity of U.S. Patent No. 5,665,772 for Obviousness and the Invalidity of U.S. Patent Nos. 6,239,124 …for Obviousness and for Obviousness-Type Double Patenting, by Par Pharmaceutical Inc.. (Fineman, Steven)… 10 October 2014 1:14-cv-01289 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Baxter
Moodys
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.